pretickt

When does CRISPR Therapeutics report earnings?

CRISPR Therapeutics AG · end-of-day data as of Nov 13, 2026

CRISPR Therapeutics
CRSP · $4.1B
$42.24-0.9%
Nov 13, 2026 · close
$50$60SepOctNov9:3016:003 months -20.3%Nov 13 · close
▲ 4
  • PT$72.45 +71.5%
  • ConsensusBuy · 23
  • Bollingerbelow lower
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • RSI32
  • Support-7.6%
  • Resistance+0.3%
  • Off 52w high-33.4%
  • Volume1.2x
  • News0.00
  • Trendsideways
  • 52w range$42–$63
  • ATR+6.3%
  • Off ATH-80.8%
▼ 4
  • FCF yield-9.3%
  • Insiders-$4.88M
  • MAs0 of 4
  • MACD-0.81

Updates with the 15-min delayed price. Not a forecast or investment advice.

CRISPR Therapeutics CRSP reports its next earnings on Thursday, Feb 11, 2027, an estimated date the company has not confirmed yet. Analysts expect EPS of -$1.17 on revenue of $11.34M. CRISPR Therapeutics beat the EPS estimate in 3 of its last 8 reports, and the stock moved ±4.9% on average the session after. The last report, on Nov 2, 2026: EPS of -$1.15 against -$1.04 expected and revenue of $12.67M against $14.75M; the stock was flat the next session.

The stock around its reports

⇔⇕$34.23$47.43$60.62$73.82Nov 24Apr 25Sep 25Feb 26Jul 26Dec 26EAEAEEEEEEE

Last close $42.24 · -23.0% over 2y · E earnings · D dividend · S split · A analyst rating change

Quarterly results

Q3 FY2026: Revenue +1,325.1% year over year, free cash flow -711.2% of revenue, operating margin -1,026.5%.

RevenueFree cash flow
Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Q3 FY2026Sep 30, 2026$12.67M-1.15-$90.1M-225.9%-1,026.5%-879.6%
Q2 FY2026Jun 30, 2026$10.18M-0.94-$86.62M-337.8%-1,127.6%-895.3%
Q1 FY2026Mar 31, 2026$1.46M-1.28-$109M-3,346.4%-8,933.3%-8,431.5%
Q4 FY2025Dec 31, 2025$864K-1.37-$93.07M-6,770.8%-17,912.5%-15,117.2%
Q3 FY2025Sep 30, 2025$889K-1.17-$84.71M-7,177.1%-14,854.8%-11,973.1%
Q2 FY2025Jun 30, 2025$892K-2.40-$114M-5,477.7%-14,918.3%-23,379.9%
Q1 FY2025Mar 31, 2025$865K-1.58-$54.15M-6,548.4%-17,158.8%-15,722.1%
Q4 FY2024Dec 31, 2024$35M-0.44-$50.28M100.0%-184.5%-106.6%